KEGG   DRUG: AlirocumabHelp
Entry
D10335                      Drug                                   

Name
Alirocumab (USAN);
Praluent (TN)
Product
Formula
C6472H9996N1736O2032S42
Exact mass
145892.049
Mol weight
145981.7606
Sequence
(Heavy chain)
EVQLVESGGG LVQPGGSLRL SCAASGFTFN NYAMNWVRQA PGKGLDWVST ISGSGGTTNY
ADSVKGRFII SRDSSKHTLY LQMNSLRAED TAVYYCAKDS NWGNFDLWGR GTLVTVSSAS
TKGPSVFPLA PSSKSTSGGT AALGCLVKDY FPEPVTVSWN SGALTSGVHT FPAVLQSSGL
YSLSSVVTVP SSSLGTQTYI CNVNHKPSNT KVDKKVEPKS CDKTHTCPPC PAPELLGGPS
VFLFPPKPKD TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST
YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT
KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQ
GNVFSCSVMH EALHNHYTQK SLSLSPG
(Light chain)
DIVMTQSPDS LAVSLGERAT INCKSSQSVL YRSNNRNFLG WYQQKPGQPPNLLIYWASTR
ESGVPDRFSG SGSGTDFTLT ISSLQAEDVA VYYCQQYYTT PYTFGQGTKL EIKRTVAAPS
VFIFPPSDEQ LKSGTASVVC LLNNFYPREA KVQWKVDNAL QSGNSQESVT EQDSKDSTYS
LSSTLTLSKA DYEKHKVYAC EVTHQGLSSP VTKSFNRGEC
(dimer; disulfide bridges: H22-H96, H145-H201, H221-L-220, H227-H'227, H230-H'230, H262-H322, H368-H426, H'22-H'96, H'145-H'201, H'221-L'220, H'262-H'322, H'368-H'426, L23-L94, L140-L200, L'23-L'94, L'140-L'200)
  Type
Peptide
Class
Cardiovascular agent
 DG01946  Hypolipidemic agent
Remark
Therapeutic category: 2189
ATC code: C10AX14
Product: D10335<JP/US>
Efficacy
Antihyperlipidemic, Anti-PCSK9 antibody
  Disease
Primary hyperlipidemia [DS:H01635]
Heterozygous familial hypercholesterolemia [DS:H00155 H01383]
Comment
Monoclonal antibody
Treatment of hypercholesterolemia
Target
PCSK9 [HSA:255738] [KO:K13050]
  Pathway
hsa04979  Cholesterol metabolism
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 C CARDIOVASCULAR SYSTEM
  C10 LIPID MODIFYING AGENTS
   C10A LIPID MODIFYING AGENTS, PLAIN
    C10AX Other lipid modifying agents
     C10AX14 Alirocumab
      D10335  Alirocumab (USAN) <JP/US>
USP drug classification [BR:br08302]
 Cardiovascular Agents
  Dyslipidemics, Other
   Alirocumab
    D10335  Alirocumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  21  Cardiovascular agents
   218  Hyperlipidemia agents
    2189  Others
     D10335  Alirocumab (USAN)
Target-based classification of drugs [BR:br08310]
 Enzymes
  Hydrolases (EC3)
   Serine peptidases
    PCSK9
     D10335  Alirocumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New Molecular Entity and New Therapeutic Biological Product Approvals
  D10335
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D10335
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D10335
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D10335
Pharmacogenomic biomarkers [br08341.html]
 Polymorphisms and germline mutations
  D10335
BRITE hierarchy
Other DBs
CAS: 1245916-14-6
PubChem: 172232429
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system